Clinical Trials Logo

Anxiety Disorders clinical trials

View clinical trials related to Anxiety Disorders.

Filter by:

NCT ID: NCT04901481 Terminated - Clinical trials for Generalized Anxiety Disorder

Empower Neuromodulation System - Pilot Study for Anxiety Treatment

Start date: September 17, 2021
Phase: N/A
Study type: Interventional

This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD). This is a pilot investigation in which participants will randomized (1:1) to the active or sham treatment.

NCT ID: NCT04784182 Terminated - Clinical trials for Breast Cancer Female

Anti-anxiety Biotics for Breast Cancer Survivors

ABBCS
Start date: July 20, 2021
Phase: N/A
Study type: Interventional

Cancer survivors experience more rapid declines in health-related quality of life which include physical and psychological comorbidities, the latter of which may be subclinical and often overlooked by primary care providers. Recently, the gut-brain axis (GBA) has been identified as a therapeutic target to improve host health. The GBA is greatly influenced by the composition of the gut microbiome, as microbial metabolites directly influence the central nervous system. Thus, prebiotics, probiotics, and synbiotics (a combination of pre- and probiotics) have emerged as a possible approach to treating anxiety symptoms. Preclinical studies suggest efficacy of synbiotics, while pre- and probiotics have only been studied in isolation in humans. This is a double-blind, placebo-controlled clinical trial in which female breast cancer survivors and/or their female relatives experiencing moderate to severe anxiety symptoms will be randomized to daily consumption of the synbiotic supplement or placebo. The previously validated Generalized Anxiety Disorder-7 (GAD-7) will be used to assess anxiety symptom severity at study screening and at each time point. The primary outcome of this study is feasibility, measured by accrual, adherence, retention, and adverse effects. Secondary outcomes relate to reduction of anxiety symptoms and other physiological changes. No study has investigated the mediating effects of gut microbiota and inflammatory markers on the ability of synbiotics to reduce anxiety symptoms. Thus, at each timepoint, phlebotomy will be conducted to determine serum levels of inflammatory cytokines and stool samples will be collected to determine alpha- and beta-diversity of the fecal microbiome as well as relative abundance of target genera. Hypothesis: this placebo-controlled study will be feasible and synbiotic treatment will result in a significant reduction in anxiety symptoms and inflammatory markers, which may be moderated by changes in the microbiome.

NCT ID: NCT04760938 Terminated - Anxiety Disorders Clinical Trials

Treating Adolescents With CBT and OBH

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to examine various behavioral, social, and emotional changes that result from engaging in an OBH and CBT treatment program designed for adolescents.

NCT ID: NCT04714164 Terminated - Clinical trials for Major Depressive Disorder

Cognitive Behavioral Therapy Group for Older Adults Delivered by Telethealth

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

The present aim of the study is to to adapt an established, manualized enhanced Group CBT (CBT-E) for seniors to a telehealth format, which will allow us to offer the group virtually during the COVID-19 pandemic.

NCT ID: NCT04612491 Terminated - Anxiety Clinical Trials

Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery

Start date: September 6, 2019
Phase:
Study type: Observational

To determine if in-office pre-operative consultation has a significant effect on the anxiety level and overall post-operative satisfaction of patients undergoing first time Mohs surgery

NCT ID: NCT04582396 Terminated - PTSD Clinical Trials

Stellate Ganglion Blockade to Reduce Cardiac Anxiety and PTSD Symptoms in Cardiac Arrest Survivors

SGB-PsychoED
Start date: March 11, 2021
Phase: N/A
Study type: Interventional

This is a pilot randomized controlled trial (RCT) to gain preliminary evidence regarding the acceptability, tolerability, safety, and efficacy of a combined intervention of Stellate Ganglion Blockade (SGB) and psychoeducation on trauma symptoms and health behaviors in patients exhibiting early PTSD symptoms after cardiac arrest (CA). Primary Aim 1 (Feasibility outcomes): Gain preliminary evidence regarding the acceptability, tolerability, and safety of conducting a randomized trial that evaluates a single SGB treatment in conjunction with psychoeducation among CA patients with early PTSD symptoms. Secondary Aim 1 (Treatment-related outcomes): Test, whether SGB/psychoeducation treatment in CA patients with clinically significant PTSD symptoms is associated with reduced cardiac anxiety, PTSD symptoms, and improved health behaviors (physical activity and sleep duration), assessed objectively by a wrist-worn accelerometer for 4 weeks post-discharge.

NCT ID: NCT04465136 Terminated - Clinical trials for Anxiety Disorders and Symptoms

CES in the Elderly With Generalized Anxiety Disorders

Start date: February 19, 2021
Phase: N/A
Study type: Interventional

The study aimed to investigate whether cranial electrotherapy stimulation(CES) could benefit anxiety symptoms, depressive symptoms, quality of sleep and quality of life in elderly patients with anxiety disorder.

NCT ID: NCT04288180 Terminated - Clinical trials for Social Anxiety Disorder

Social Anxiety Virtual Reality Study

SAVR
Start date: January 15, 2020
Phase:
Study type: Observational

This project aims to validate a virtual reality paradigm that assesses maladaptive avoidance behavior in social anxiety disorder. It also aims to generate a significant scientific advance by testing the hypothesis that maladaptive avoidance maintains anxiety through disruptions in safety learning.

NCT ID: NCT04286594 Terminated - Anxiety Clinical Trials

A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of whole plant, hemp-derived CBD twice daily for six weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. Quality of life, sleep, general health, and cognitive function will also be assessed.

NCT ID: NCT04274114 Terminated - Clinical trials for Generalized Anxiety Disorder

Treatment of Adults With Generalized Anxiety Disorder Using Glutamine

Start date: January 18, 2019
Phase: Phase 2
Study type: Interventional

The objective of this randomized clinical trial is to examine the efficacy of L-glutamine for the treatment of generalized anxiety disorder compared versus placebo.